Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A multigenic program mediating breast cancer metastasis to bone
20032.0k citationsYibin Kang, Peter M. Siegel et al.Cancer Cellprofile →
Countries citing papers authored by Marija Drobnjak
Since
Specialization
Citations
This map shows the geographic impact of Marija Drobnjak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marija Drobnjak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marija Drobnjak more than expected).
This network shows the impact of papers produced by Marija Drobnjak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marija Drobnjak. The network helps show where Marija Drobnjak may publish in the future.
Co-authorship network of co-authors of Marija Drobnjak
This figure shows the co-authorship network connecting the top 25 collaborators of Marija Drobnjak.
A scholar is included among the top collaborators of Marija Drobnjak based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Marija Drobnjak. Marija Drobnjak is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kang, Yibin, Peter M. Siegel, Weiping Shu, et al.. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6). 537–549.1970 indexed citations breakdown →
7.
Solit, David B., Fuzhong F. Zheng, Marija Drobnjak, et al.. (2002). 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.. PubMed. 8(5). 986–93.354 indexed citations
8.
Como, Charles J. Di, Marshall Urist, Irina Babayan, et al.. (2002). p63 expression profiles in human normal and tumor tissues.. PubMed. 8(2). 494–501.432 indexed citations
9.
Fox, William D., Brian Higgins, Marija Drobnjak, et al.. (2002). Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.. PubMed. 8(10). 3226–31.83 indexed citations
Osman, Islam, Howard I. Scher, Marija Drobnjak, et al.. (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.. PubMed. 7(9). 2643–7.130 indexed citations
12.
Butler, Lisa M., David B. Agus, Brian Higgins, et al.. (2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.. PubMed. 7(4). 962–70.105 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.